519 studies found for:    multiple myeloma | Open Studies | multiple myeloma
Show Display Options
Rank Status Study
21 Not yet recruiting GO-203-2C + Bortezomib For Relapsed Or Refractory MM
Conditions: Multiple Myeloma;   Multiple Myeloma in Relapse;   Refractory Multiple Myeloma
Interventions: Drug: GO-203-2C;   Drug: Bortezomib
22 Recruiting Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: bortezomib;   Drug: lenalidomide;   Other: laboratory biomarker analysis
23 Recruiting Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs
Condition: Multiple Myeloma
Intervention: Drug: Bendamustine + Dexamethasone + Thalidomide
24 Recruiting High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: BeEAM
25 Recruiting A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities
Conditions: Solid Tumors;   Multiple Myeloma
Intervention: Drug: TAS-120
26 Recruiting A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: AMG 224
27 Recruiting Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
Conditions: Extramedullary Plasmacytoma;   Isolated Plasmacytoma of Bone;   Light Chain Deposition Disease;   Primary Systemic Amyloidosis;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: cisplatin;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: bortezomib;   Drug: thalidomide;   Drug: melphalan;   Procedure: autologous stem cell transplant
28 Recruiting TUMOR-ASSOCIATED ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR MULTIPLE MYELOMA
Condition: Multiple Myeloma
Intervention: Biological: TAA-specific CTLs
29 Recruiting A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Condition: Smoldering Multiple Myeloma (SMM)
Intervention: Drug: daratumumab
30 Unknown  Prognostic Potential of Cell Surface Markers and Pim Kinases in Multiple Myeloma
Condition: Multiple Myeloma
Intervention:
31 Recruiting An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients
Condition: Multiple Myeloma
Intervention: Other: No Intervention
32 Recruiting Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
Conditions: Multiple Myeloma;   Renal Impairment
Interventions: Drug: 4 mg Oral POM + 40 mg Oral DEX;   Drug: 2 mg Oral POM + 40 mg Oral DEX
33 Recruiting A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Elotuzumab;   Drug: Pomalidomide;   Drug: Bortezomib;   Drug: Dexamethasone
34 Recruiting Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])
Condition: Multiple Myeloma
Intervention:
35 Recruiting Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Condition: Relapsed/Refractory Multiple Myeloma
Interventions: Drug: ABT-199;   Drug: Dexamethasone
36 Recruiting Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: lenalidomide;   Biological: pidilizumab;   Other: pharmacological study;   Other: laboratory biomarker analysis
37 Recruiting Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.
Condition: Multiple Myeloma in Older Patients
Intervention: Other: Vulnerability and therapeutic changes in older patients with multiple myeloma.
38 Recruiting An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
Conditions: Hodgkin Lymphoma,;   Mature T-cell Lymphoma;   Multiple Myeloma
Intervention: Drug: lenalidomide (Revlimid) and romidepsin (Istodax)
39 Recruiting Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138
Condition: Multiple Myeloma
Intervention: Biological: CART-138 cells
40 Unknown  High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Drug: melphalan;   Procedure: autologous hematopoietic stem cell transplantation

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years